Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Urologic / Genitourinary Cancers

35 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    Bladder

    VICCURO1322

    03/28/2014

    Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

    Diagnostic

    Kidney (Renal Cell)

    VICCURO15104

    02/24/2017

    Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients with CKD (CEUS CKD)

    Diagnostic

    Prostate

    VICCURO15140

    01/18/2016

    Analysis of Cell-Free DNA (cfDNA) in Men with Elevated PSA Levels

    Health Services Research

    Prostate

    VICCURO1589

    03/16/2016

    A Prospective Observational Cohort Study of Patients with Castration- Resistant Prostate Cancer (CRPC) in the United States

    Health Services Research

    Prostate

    VICCURO1638

    06/29/2015

    Patient-Centered Treatment Decision-Making in Advanced Prostate Cancer

    Other

    Bladder

    VICCURO1717

    04/06/2017

    Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection of Primary Bladder Cancers in Urine Samples from a Cohort of Patients with Hematuria

    Other

    Prostate

    VICCURO16112

    10/25/2016

    Prospective Observational Trial of an Absorbable Hydrogel Spacer in Prostate Cancer Radiotherapy

    Other

    Bladder

    VICCURO15125

    07/08/2016

    Clinical Validation of a Urine-Based Assay with Genomic and Epigenomic Markers for Predicting Recurrence during Surveillance for Non-Muscle Invasive Bladder Cancer

    Other

    Bladder
    Urologic

    VICCURO15108

    05/31/2016

    Urinary Biomarkers in the Detection of Transitional Cell Carcinoma of the Bladder

    Other

    Bladder

    VICCURO1618

    05/24/2016

    Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma A Multicenter, Prospective Blinded Pivotal Study

    Other

    Prostate

    URO70807-M

    05/10/2012

    Men's Eating and Living Study: A Randomized trial of diet to alter disease progression in prostste cancer patients on active surveillance

    Supportive Care

    Prostate

    VICCURO16133

    03/31/2017

    Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

    Treatment

    Kidney (Renal Cell)

    VICCURO16135

    11/15/2017

    A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer after Treatment with PD-1 or PD-L1 Inhibitors

    Treatment

    Prostate

    VICCURO1626

    09/25/2017

    A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have Progressed Following Treatment with an Androgen Pathway Inhibitor

    Treatment

    Bladder
    Kidney (Renal Cell)
    Uterine

    VICCURO16158

    09/07/2017

    A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (ANTI−PD-L1 Antibody) as Monotherapy and in Combination with Platinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma

    Treatment

    Kidney (Renal Cell)
    Lung
    Melanoma
    Non Small Cell

    VICCURO16101

    08/10/2017

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

    Treatment

    Bladder

    VICCURO1723

    08/10/2017

    An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and/or a TSC2 Mutation

    Treatment

    Urologic

    VICCURO1724

    07/10/2017

    A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma

    Treatment

    Kidney (Renal Cell)

    ECOGUROEA8143

    06/09/2017

    PHIII Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.

    Treatment

    Kidney (Renal Cell)

    VICCURO16120

    05/15/2017

    A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy

    Treatment

    Kidney (Renal Cell)

    VICCURO1653

    03/02/2017

    A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of AVELUMAB (MSB0010718C) in Combination with AXITINIB (INLYTA?) versus SUNITINIB (SUTENT?) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

    Treatment

    Urologic

    VICCURO1668

    01/11/2017

    A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

    Treatment

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Ovarian
    Uterine

    VICCPHI1676

    11/04/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Uterine

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    Prostate

    VICCURO1677

    08/09/2016

    Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients with Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study

    Treatment

    Bladder
    Colon
    Gastric/Gastroesophageal
    Kidney (Renal Cell)
    Rectal
    Urologic

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    Prostate

    NRGUROR0924

    03/10/2016

    Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

    Treatment

    Bladder

    ECOGUROS1314

    01/18/2016

    A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

    Treatment

    Bladder
    Breast
    Hematologic
    Leukemia
    Lymphoma
    Multiple Myeloma
    Myelodysplastic Syndrome
    Pancreatic
    Urologic

    VICCHEMP1558

    10/09/2015

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    Bladder
    Urologic

    ECOGUROEA8141

    08/27/2015

    A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

    Treatment

    Prostate

    VICCURO1540

    07/08/2015

    A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men with High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy. MDV3100-13

    Treatment

    Prostate

    CTSUALLIANCEURO031201-M

    11/21/2014

    URO A031201: Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

    Treatment

    Bladder
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Neuro-Oncology
    Ovarian
    Urologic
    Uterine

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

    Treatment

    Prostate

    CTSUUROS1216-M

    01/16/2014

    A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

    Treatment

    Prostate

    CTSUUROC90203-M

    11/05/2007

    A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer


    Print this page for your doctor